Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded accessStudy achieving primary endpoints of safety, tolerability, and efficacy by resolving/curing bacterial infections in patients with diabetic foot ulcersRECCE® 327 dosed daily or every second day for 14 days is considered to be safe and well-toleratedAdditional clinical sites to be launched in Australia, and additional clinical trials will be launched internationally in diab
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has received approval from the human research ethics committee (HREC) to kick off its Phase I/II clinical.